Genprex

Category: Blog Posts

A Potential NSCLC Treatment for Large Patient Populations

Today’s cancer treatment options are not one-size-fits-all. But Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based on a unique proprietary technology platform, is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies….

Read More

Big Excitement in Gene Therapy at ASGCT 2019

Earlier this month, Genprex’s President and Chief Operating Officer, Julien Pham attended the American Society of Gene & Cell Therapy’s 22ndAnnual Meeting in Washington, D.C., which brings together industry professionals committed to advancing knowledge, awareness and education of gene and cell therapy. This meeting serves as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society….

Read More

How Genprex Differs From “Traditional” Gene Therapy Approaches

Gene therapy is a big and trending topic in the world of medicine and has recently been making headlines as large pharmaceutical companies have been ramping up acquisitions of gene therapy companies. So how exactly does gene therapy work? There are a couple of “traditional” approaches to this generally newer treatment option for rare diseases and cancer….

Read More

Thermo Fisher and Brammer Bio Deal Illustrates Rapid Growth for Gene Therapy

Thermo Fisher recently announced it is buying Brammer Bio, which provides viral vector manufacturing services for gene and cell therapy companies. This acquisition is one of the many we have seen recently, as several other large pharmaceutical companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, including Roche’s acquisition of Spark Therapeutics, Biogen’s buying of Nightstar Therapeutics and Pfizer’s purchase of Vivet Therapeutics….

Read More

IASLC 2019: Bringing Together Collaboration, Science and Hope for the Future

Last month, Genprex’s President and Chief Operating Officer, Julien Pham, attended the IASLC 2019 Targeted Therapies of Lung Cancer Meeting in Santa Monica, California. This meeting brought together a variety of key players working on the newest therapies for lung cancer including researchers, oncologists, physicians, patient advocacy groups and even clinical-stage companies, such as Genprex….

Read More

Gene Therapy Now Coming into the Mainstream as Treatment Option for Serious Diseases

Roche’s acquisition of Spark Therapeutics confirms that gene therapy has finally made its debut as a treatment option for serious diseases

Chemotherapy, radiation, and more recently, immunotherapy have been the primary treatments for patients with cancer, and there has been little progress in terms of “huge medical breakthroughs” for cancer treatment for many years.  …

Read More